Drugs / Lime Powder Regimen
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03258190 | Jul 2014 → Jun 2018 | urolithiasis | Chulalongkorn University | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Lime Powder Regimen | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03258190 ↗ |
| Known as | LPR | “Lime powder regimen (LPR) is a lime-derived composition enriches with citrate/citric acid and potassium.” NCT03258190 ↗ |
| Action | Inhibit | “LPR inhibited the growth of calcium oxalate monohydrate (COM) crystals in dose-dependent manner” PMID 25588323 ↗ Jan 2015 |
| Route | Oral | “No acute toxicity was detected in mice orally fed with LPR (10 g/kg).” PMID 25588323 ↗ Jan 2015 |